FDA Drug recall D-1008-2020
Daptomycin, 500MG in 0.9% NACL 100ML Injectable Redline Specialty Pharmacy, 2415 Osborne Drive E, #100 Hastings, NE 68901
- FDA Drug
- Class II
- terminated
- Published 2020-03-18
On 2020-03-18 the FDA classified a Class II recall of Daptomycin, 500MG in 0.9% NACL 100ML Injectable Redline Specialty Pharmacy, 2415 Osborne Drive E, #100 Hastings, NE 68901 by Redline Pharmacy Solutions, citing lack Of Processing Controls.
Read the official FDA Drug notice
| Agency | FDA Drug |
|---|---|
| Recall number | D-1008-2020 |
| Classification | Class II |
| Status | terminated |
| Initiated | 2020-02-24 |
| Published | 2020-03-18 |
| Last updated | 2026-09-13 11:52 UTC |
| Company | Redline Pharmacy Solutions |
| Distribution | NE |
Product
Daptomycin, 500MG in 0.9% NACL 100ML Injectable Redline Specialty Pharmacy, 2415 Osborne Drive E, #100 Hastings, NE 68901
Reason
Lack Of Processing Controls
Identifiers
| code_info | Lots 02242020@3, 02242020@9 |
|---|
Status history
No status changes recorded since RecallRadar first saw this recall on 2026-09-13 11:52 UTC. Current status: terminated.
Source
Official record: https://api.fda.gov/drug/enforcement.json?search=recall_number:%22D-1008-2020%22
RecallRadar indexes public recall notices from the FDA, USDA FSIS, and CPSC. The official agency notice is the authoritative source. Always confirm details at the linked source before acting.